|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Livraghi T, Mäkisalo H and Line PD:
Treatment options in hepatocellular carcinoma today. Scand J Surg.
100:22–29. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Malan-Müller S, Hemmings SM and Seedat S:
Big effects of small RNAs: A review of microRNAs in anxiety. Mol
Neurobiol. 47:726–739. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Almeida MI, Reis RM and Calin GA: MicroRNA
history: Discovery, recent applications, and next frontiers. Mutat
Res. 717:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Calin GA and Croce CM: MicroRNA-cancer
connection: The beginning of a new tale. Cancer Res. 66:7390–7394.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Manikandan J, Aarthi JJ, Kumar SD and
Pushparaj PN: Oncomirs: The potential role of non-coding microRNAs
in understanding cancer. Bioinformation. 2:330–334. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fiorino S, Bacchi-Reggiani ML, Visani M,
Acquaviva G, Fornelli A, Masetti M, Tura A, Grizzi F, Zanello M,
Mastrangelo L, et al: MicroRNAs as possible biomarkers for
diagnosis and prognosis of hepatitis B- and
C-related-hepatocellular-carcinoma. World J Gastroenterol.
22:3907–3936. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang JT, Liu SM, Ma H, Yang Y, Zhang X,
Sun H, Zhang X, Xu J and Wang J: Systematic review and
meta-analysis: Circulating miRNAs for diagnosis of hepatocellular
carcinoma. J Cell Physiol. 231:328–335. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Negrini M, Gramantieri L, Sabbioni S and
Croce CM: microRNA involvement in hepatocellular carcinoma.
Anticancer Agents Med Chem. 11:500–521. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qi J, Rice SJ, Salzberg AC, Runkle EA,
Liao J, Zander DS and Mu D: MiR-365 regulates lung cancer and
developmental gene thyroid transcription factor 1. Cell Cycle.
11:177–186. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun R, Liu Z, Ma G, Lv W, Zhao X, Lei G
and Xu C: Associations of deregulation of mir-365 and its target
mRNA TTF-1 and survival in patients with NSCLC. Int J Clin Exp
Pathol. 8:2392–2399. 2015.PubMed/NCBI
|
|
14
|
Bai J, Zhang Z, Li X and Liu H:
MicroRNA-365 inhibits growth, invasion and metastasis of malignant
melanoma by targeting NRP1 expression. Cancer Biomark. 15:599–608.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gao J, Zhao P, Chen X, Wang W, Li Y, Xi W,
Zhang W, Hu P, Wang T and Shan L: miR-365 inhibits proliferation
and promotes apoptosis of SOSP9607 osteosarcoma cells. Xi Bao Yu
Fen Zi Mian Yi Xue Za Zhi. 32:44–48. 2016.(In Chinese). PubMed/NCBI
|
|
16
|
Nie J, Liu L, Zheng W, Chen L, Wu X, Xu Y,
Du X and Han W: microRNA-365, down-regulated in colon cancer,
inhibits cell cycle progression and promotes apoptosis of colon
cancer cells by probably targeting cyclin D1 and Bcl-2.
Carcinogenesis. 33:220–225. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo SL, Ye H, Teng Y, Wang YL, Yang G, Li
XB, Zhang C and Yang X, Yang ZZ and Yang X: Akt-p53-miR-365-cyclin
D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN
deficiency. Nat Commun. 4:25442013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou M, Zhou L, Zheng L, Guo L, Wang Y,
Liu H, Ou C and Ding Z: miR-365 promotes cutaneous squamous cell
carcinoma (CSCC) through targeting nuclear factor I/B (NFIB). PLoS
One. 9:e1006202014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou M, Liu W, Ma S, Cao H, Peng X, Guo L,
Zhou X, Zheng L, Guo L, Wan M, et al: A novel onco-miR-365 induces
cutaneous squamous cell carcinoma. Carcinogenesis. 34:1653–1659.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hamada S, Masamune A, Miura S, Satoh K and
Shimosegawa T: MiR-365 induces gemcitabine resistance in pancreatic
cancer cells by targeting the adaptor protein SHC1 and
pro-apoptotic regulator BAX. Cell Signal. 26:179–185. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen Z, Huang Z, Ye Q, Ming Y, Zhang S,
Zhao Y, Liu L, Wang Q and Cheng K: Prognostic significance and
anti-proliferation effect of microRNA-365 in hepatocellular
carcinoma. Int J Clin Exp Pathol. 8:1705–1711. 2015.PubMed/NCBI
|
|
22
|
Liu S, Zhang W, Liu K, Ji B and Wang G:
Silencing ADAM10 inhibits the in vitro and in vivo growth of
hepatocellular carcinoma cancer cells. Mol Med Rep. 11:597–602.
2015.PubMed/NCBI
|
|
23
|
Crawford HC, Dempsey PJ, Brown G, Adam L
and Moss ML: ADAM10 as a therapeutic target for cancer and
inflammation. Curr Pharm Des. 15:2288–2299. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moss ML, Stoeck A, Yan W and Dempsey PJ:
ADAM10 as a target for anti-cancer therapy. Curr Pharm Biotechnol.
9:2–8. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang W, Liu S, Liu K, Wang Y, Ji B, Zhang
X and Liu Y: A disintegrin and metalloprotease (ADAM)10 is highly
expressed in hepatocellular carcinoma and is associated with tumour
progression. J Int Med Res. 42:611–618. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yue Y, Shao Y, Luo Q, Shi L and Wang Z:
Downregulation of ADAM10 expression inhibits metastasis and
invasiveness of human hepatocellular carcinoma HepG2 cells. BioMed
Res Int. 2013:4345612013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang W, Liu S, Liu K, Ji B, Wang Y and
Liu Y: Knockout of ADAM10 enhances sorafenib antitumor activity of
hepatocellular carcinoma in vitro and in vivo. Oncol Rep.
32:1913–1922. 2014.PubMed/NCBI
|
|
28
|
Liu S, Liu K, Zhang W, Wang Y, Jin Z, Jia
B and Liu Y: miR-449a inhibits proliferation and invasion by
regulating ADAM10 in hepatocellular carcinoma. Am J Transl Res.
8:2609–2619. 2016.PubMed/NCBI
|
|
29
|
Wu G, Zheng K, Xia S, Wang Y, Meng X, Qin
X and Cheng Y: MicroRNA-655-3p functions as a tumor suppressor by
regulating ADAM10 and β-catenin pathway in hepatocellular
carcinoma. J Exp Clin Cancer Res. 35:892016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bai S, Nasser MW, Wang B, Hsu SH, Datta J,
Kutay H, Yadav A, Nuovo G, Kumar P and Ghoshal K: MicroRNA-122
inhibits tumorigenic properties of hepatocellular carcinoma cells
and sensitizes these cells to sorafenib. J Biol Chem.
284:32015–32027. 2009. View Article : Google Scholar : PubMed/NCBI
|
